Clinical Trial Update: A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing 21 mg nicotine transdermal patches from two manufacturers, to assess interchangeability in healthy adult smokers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• Nicoderm CQ (nicotine patch)

Snippet

Sponsor: HALEON | Conditions: Tobacco Use Disorder | Phase 1 | Status: COMPLETED | Results posted: 2024-03-21